Transverse myelitis: Difference between revisions
From IDWiki
(Imported from text file) Â |
(→â€) |
||
Line 1: | Line 1: | ||
== |
==Definition== |
||
* |
*Heterogeneous condition characterized by inflammation of the spinal cord |
||
== |
==Etiology== |
||
*CNS disorders |
|||
* Post-infectious |
|||
**[[Multiple sclerosis]] |
|||
* Post vaccination |
|||
**[[Neuromyelitis optica]] |
|||
⚫ | |||
**[[Acute disseminated encephalomyelitis]] (ADEM) |
|||
** VZV |
|||
**[[Myelin oligodendrocyte glyocprotein antibody-associated disorder]] |
|||
** CMV |
|||
⚫ | |||
** Etc. |
|||
⚫ | |||
⚫ | |||
**[[Sjögren syndrome]] |
|||
⚫ | |||
**[[Systemic lupus erythematosus]] |
|||
* Acquired demyelinating disease |
|||
**Others: [[ankylosing spondylitis]], [[antiphospholipid antibody syndrome]], [[Behçet disease]], [[mixed connective tissue disease]], [[rheumatoid arthritis]], and [[systemic sclerosis]] |
|||
** MS |
|||
⚫ | |||
⚫ | |||
**[[Enteroviruses]], especially D68 and EV71 |
|||
**[[West Nile virus]] |
|||
**[[Herpesviridae]], including [[HSV]], [[VZV]], [[EBV]], [[CMV]], and [[HHV-6]] |
|||
**[[HIV]] |
|||
**[[HTLV-1]] |
|||
**[[Zika virus]] |
|||
**[[Lyme disease]] |
|||
**[[Mycoplasma species]] |
|||
**[[Treponema pallidum]] |
|||
*Paraneoplastic, most often secondary to [[small cell lung cancer]] |
|||
**Anti-Hu disease |
|||
**Anti-CRMP5 disease |
|||
⚫ | |||
== |
==Clinical Manifestations== |
||
*Presentation is either acute or subacute, usually starting with sensory changes, weakness, or pain |
|||
* Motor and sensory deficits |
|||
*Characterized by both motor and sensory deficits, with specific deficits depending on the spinal level of the lesion |
|||
== |
==Investigations== |
||
* |
*MRI spine '''with gadolinium''', showing characteristic T2 hyperintensity without evidence of cord compression |
||
*CSF showing pleocytosis |
|||
== |
==Diagnosis== |
||
* |
*Sensorimotor and autonomic spinal cord dysfunction |
||
** |
**Generally bilateral but may be asymmetric |
||
* |
*Clearly defined sensory level |
||
*Bilateral signs and symptoms |
|||
* |
*Progression peaking between 4h and 21d after onset |
||
* |
*Demonstration of spinal cord inflammation |
||
** |
**Cerebrospinal fluid with pleocytosis or increased IGG |
||
** |
**MRI with gadolinium |
||
* |
*Exclusion of compressive, postradiation, neoplastic, and vascular causes |
||
== |
==Management== |
||
* |
*Determine cause |
||
* |
*Consider high-dose steroids 1g/d x3-5 days |
||
* |
*Thromboembolism prophylaxis |
||
* |
*Symptom management for pain and spasticity |
||
** |
**Muscle relaxants |
||
* |
*Rehab (PT/OT) |
||
* |
*Follow-up investigations |
||
** |
**Repeat MRI |
||
[[Category:Neurology]] |
[[Category:Neurology]] |
Revision as of 14:18, 29 July 2020
Definition
- Heterogeneous condition characterized by inflammation of the spinal cord
Etiology
- CNS disorders
- Systemic inflammatory disorders
- Infectious
- Enteroviruses, especially D68 and EV71
- West Nile virus
- Herpesviridae, including HSV, VZV, EBV, CMV, and HHV-6
- HIV
- HTLV-1
- Zika virus
- Lyme disease
- Mycoplasma species
- Treponema pallidum
- Paraneoplastic, most often secondary to small cell lung cancer
- Anti-Hu disease
- Anti-CRMP5 disease
- Idiopathic
Clinical Manifestations
- Presentation is either acute or subacute, usually starting with sensory changes, weakness, or pain
- Characterized by both motor and sensory deficits, with specific deficits depending on the spinal level of the lesion
Investigations
- MRI spine with gadolinium, showing characteristic T2 hyperintensity without evidence of cord compression
- CSF showing pleocytosis
Diagnosis
- Sensorimotor and autonomic spinal cord dysfunction
- Generally bilateral but may be asymmetric
- Clearly defined sensory level
- Bilateral signs and symptoms
- Progression peaking between 4h and 21d after onset
- Demonstration of spinal cord inflammation
- Cerebrospinal fluid with pleocytosis or increased IGG
- MRI with gadolinium
- Exclusion of compressive, postradiation, neoplastic, and vascular causes
Management
- Determine cause
- Consider high-dose steroids 1g/d x3-5 days
- Thromboembolism prophylaxis
- Symptom management for pain and spasticity
- Muscle relaxants
- Rehab (PT/OT)
- Follow-up investigations
- Repeat MRI